Avadel Pharmaceu Stock Price, News & Analysis

Avadel Pharmaceuticals (AVDL) will present 14 abstracts, including 4 oral presentations, at SLEEP 2025 (June 8-11, Seattle) showcasing new data for LUMRYZ™, their once-nightly narcolepsy treatment. Key highlights include: - Interim REFRESH study results showing clinically significant efficacy in patients switching from twice-nightly to once-nightly oxybate - Post-hoc REST-ON trial analysis demonstrating improved Epworth Sleepiness Scale scores to normal levels in severely sleepy patients - Data showing LUMRYZ participants reported approximately 50% fewer hypnagogic/hypnopompic hallucination events versus placebo - Long-term RESTORE study results (median 503 days) showing only 4% discontinuation rate due to treatment-related adverse events - Evidence of improvement in sleep-related eating disorder (SRED) when switching from twice-nightly oxybates to LUMRYZ

Avadel Pharmaceuticals (Nasdaq: AVDL) announced its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 10:30 a.m. ET. The presentation will be available via webcast on the company's investor relations website at investors.avadel.com, with the recording remaining accessible for 90 days after the event.

Avadel Pharmaceuticals (NASDAQ: AVDL) has appointed Susan Rodriguez as Chief Operating Officer in a newly created position. Rodriguez, with over 30 years of life sciences experience, will lead the company's commercial strategy and operations, including supply chain. She previously served as Chief Commercial Officer at Ardelyx and CEO of Tolmar Pharmaceuticals.

The appointment comes at a crucial time as Avadel scales up to meet increasing patient demand for LUMRYZ in the narcolepsy community and works toward potential label expansion to idiopathic hypersomnia. Rodriguez's extensive experience includes successful launches of first-in-class therapies and leadership roles at Abbott and TAP Pharmaceuticals.

Avadel Pharmaceuticals (Nasdaq: AVDL) announced its upcoming participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, May 20 at 12:00 p.m. ET. Investors can access both the live webcast and a 90-day archived recording of the presentation through Avadel's Investor Relations website at investors.avadel.com.

Avadel Pharmaceuticals (NASDAQ: AVDL) has announced the approval of inducement awards for nine new employees by its Board's Compensation Committee. The awards consist of non-statutory options to purchase 51,700 ordinary shares under the company's 2021 Inducement Plan. These options come with a ten-year term and follow a four-year vesting schedule: 25% vests after one year of employment, with the remaining portions vesting equally on the second, third, and fourth anniversaries. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment acceptance.

Avadel Pharmaceuticals (AVDL) reported strong Q1 2025 financial results and raised its guidance. The company generated $52.5 million in net revenue from LUMRYZ sales, marking a 93% increase year-over-year. Patient count reached 2,800 as of March 31, 2025, adding 300 new patients in Q1 and showing a 100% increase from Q1 2024. Avadel raised its 2025 guidance, now expecting $255-265 million in net product revenue and $30-40 million in cash flow. The Federal Circuit ruled in Avadel's favor, allowing the company to pursue FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH). The Phase 3 REVITALYZ study for IH is on track to complete enrollment by end of 2025. The company's Q1 net loss improved to $4.9 million ($0.05 per share) compared to $27.3 million ($0.30 per share) in Q1 2024.

The United States Court of Appeals for the Federal Circuit has ruled in Avadel Pharmaceuticals' (NASDAQ: AVDL) favor, overturning key portions of a Delaware Court injunction regarding LUMRYZ™. The Federal Circuit vacated restrictions that previously prevented Avadel from seeking FDA approval for LUMRYZ beyond narcolepsy treatment. The ruling also lifts prohibitions on conducting new clinical trials and offering open-label extensions to trial participants.

The company's REVITALYZ™ Phase 3 trial for Idiopathic Hypersomnia (IH) remains on schedule, with patient enrollment expected to complete by end of 2025. This double-blind, placebo-controlled study will evaluate LUMRYZ's efficacy and safety in approximately 150 adult IH patients, including those switching from immediate-release oxybates and new participants.

Avadel Pharmaceuticals (Nasdaq: AVDL), a biopharmaceutical company dedicated to transforming medicines to transform lives, has scheduled its first quarter 2025 financial results conference call and webcast for May 7, 2025, at 8:00 a.m. ET.

The corporate update and financial results discussion will cover the quarter ended March 31, 2025. Interested participants can access the live audio webcast through the investor relations section at www.avadel.com. The webcast recording will remain available on the company's website for 90 days after the event.

Key Details:

• Event: Q1 2025 Financial Results and Corporate Update
• Date: Wednesday, May 7, 2025
• Time: 8:00 a.m. ET
• Access: Conference call registration required
• Registration Notice: Participants should register at least 10 minutes before the call

Avadel Pharmaceuticals (AVDL) and nference published real-world data analysis on sodium oxybate treatment patterns in narcolepsy patients in the Journal of Clinical Neuroscience. The study analyzed 4,387 Mayo Clinic patients with narcolepsy, including 351 treated with immediate-release sodium oxybate.

Key findings revealed:

• No significant differences in comorbidity rates between treated and untreated groups, including hypertension (21.1% vs 21.4%) and coronary artery disease (7.1% in both groups)
• Approximately one-third of patients discontinued treatment, primarily due to lack of efficacy
• Inability to wake up was the most common reason for missing the second nightly dose
• Both groups showed high rates of insomnia (approximately 43%)

The study highlights challenges with middle-of-the-night sodium oxybate dosing and reduced efficacy when second doses are missed, suggesting potential underutilization of the therapy due to dosing requirements.